Search

Your search keyword '"D.P. Carbone"' showing total 21 results
Start Over Author "D.P. Carbone"
21 results on '"D.P. Carbone"'

3. EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial

Author

D.H. Owen, G.A. Durm, L. Wei, C. Pilcher, S. Ferguson, B. Benner, M. Jukich, V. Sukrithan, B. Konda, H. Savardekar, D. Spakowicz, E. Schwarz, R.O. Norman, R. Wesolowski, W.E. Carson, J. Kaufman, A. Alahmadi, R. Memmott, P. Shields, K. He, E.M. Bertino, C.J. Presley, D.P. Carbone, and G.A. Otterson

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

5. OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial

Author

D.H. Owen, L. Wei, B. Benner, C. Pilcher, G. Christenson, S. Ferguson, M. Jukich, V. Sukrithan, B. Konda, M. Shah, H. Savardekar, E. Schwarz, R.O. Norman, R. Wesolowski, W.E. Carson, J. Kaufman, A. Alahmadi, R. Memmott, P. Shields, K. He, E.M. Bertino, C.J. Presley, D.P. Carbone, C. Verschraegen, and G.A. Otterson

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

6. OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing

Author

F. Oezkan, S. Hilz, J. Grindheim, A. Wallace, M. Seweryn, A. Reuben, J. Zhang, D.H. Owen, A. Nicholas, M. Yadav, D. Nagarkar, P. de Almeida, P. Ebert, E. Osborne, A. Johnson, J.M. Lee, P. Bunn, B.E. Johnson, J. Chaft, M.G. Kris, V.W. Rusch, K. Schulze, D.J. Kwiatkowski, I.I. Wistuba, and D.P. Carbone

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

8. 1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA

Author

T. John, T-E. Ciuleanu, M. Cobo Dols, M. Schenker, B. Zurawski, J. Menezes, E.A. Richardet, J. Bennouna, Y. Cheng, E. Felip, O.J. Juan Vidal, A. Alexandru, L. Paz-Ares, S. Lu, M. Reck, N. Hu, X. Zhang, D.J. Grootendorst, L. Eccles, and D.P. Carbone

Subjects
Oncology, Hematology
Published
2022

13. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles d’un doublet de chimiothérapie à base de sels de platine (CT) vs 4 cycles de chimiothérapie en 1ère ligne (1L) de traitement du cancer bronchique non à petites cellules (CBNPC) au stade avancé : données du suivi à 2 ans de l’étude CheckMate 9LA (CM 9LA)

Author

A. Scherpereel, M. Reck, T.E. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, J. Bennouna, E. Felip, O. Juan-Vidal, A. Alexandru, H. Sakai, S. Lu, L. Paz-Ares, D.P. Carbone, A. Memaj, S. Marimuthu, P. Tran, and T. John

Subjects
Pulmonary and Respiratory Medicine
Published
2022

14. Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’

Author

M. Reck, T.-E. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, J. Bennouna, E. Felip, O. Juan-Vidal, A. Alexandru, H. Sakai, A. Lingua, F. Reyes, P.-J. Souquet, P. De Marchi, C. Martin, M. Pérol, A. Scherpereel, S. Lu, L. Paz-Ares, D.P. Carbone, A. Memaj, S. Marimuthu, X. Zhang, P. Tran, and T. John

Subjects
Cancer Research, Oncology
Published
2021

19. PV-0040: Patterns of care for the elderly with non-surgically treated stage III non-small cell lung cancer

Author

James L. Fisher, Jose G. Bazan, Meng Xu-Welliver, K.E. Haglund, D.P. Carbone, Eric D. Miller, Gregory A. Otterson, E.M. Bertino, Kai He, J.C. Gre cula, P.G. Shields, and Terence M. Williams

Subjects
Oncology, Patterns of care, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Stage III Non-Small Cell Lung Cancer
Published
2018

20. The Molecular Biology of Lung Cancer

Author

T. Ishida and D.P. Carbone

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Lung cancer, medicine.disease, business
Published
1997

21. Dendritic cells (DC) loaded with apoptotic, allogeneic melanoma cells reduce tumor progression and improve survival in a murine immunotherapy model

Author

Mark C. Kelley, D.P. Carbone, and S. Knobel

Subjects
business.industry, medicine.medical_treatment, Melanoma, Immunotherapy, medicine.disease, Tumor antigen, CTL, medicine.anatomical_structure, Apoptosis, Tumor progression, Immunology, Cancer research, Medicine, Cytotoxic T cell, Surgery, Bone marrow, business
Abstract

Introduction: DC loaded with apoptotic, syngeneic melanoma cells slow tumor growth and improve survival in a murine immunotherapy model. The use of allogeneic cells as a source of tumor antigen could increase the clinical applicability of this therapy, so we investigated the efficacy of DC loaded with apoptotic, allogeneic cells in this model. Methods: DC were cultured from bone marrow from C-57/BL-6 mice with GMCSF (10 ng/ml), IL-4 (5 ng/ml). Syngeneic B-16 or allogeneic K-1735 melanoma cells were irradiated (20 Gy) to induce apoptosis and cultured with DC at a 1:1 ratio for 48 hr to make DC/Apo vaccine. C-57/BL-6 mice (n = 6) were injected with 2.5 x 105 B-16 SQ and treated with 1 x 106 DC/Apo vaccine cells SQ or saline control weekly x4 starting 5 days after tumor implantation. In other experiments, splenocytes were harvested from control and immunized tumor-bearing animals at day 30 and stimulated weekly x2 with IFN-gamma treated, irradiated B-16 cells. Cytotoxic T lymphocyte (CTL) assays were performed with B-16 targets for 48 hr and % specific lysis calculated. Results: Summarized in table 1. TABLE—ABSTRACT 35. Tumor size Median survival 60d survival Specific lysis# Control 11 ± 6 mm 31 days 0% 9 ± 12% DC/ApoB-16 3 ± 3 mm∗ >60 days∗ 67%∗ 63 ± 20%∗ DC/ApoK-1735 4 ± 3 mm∗ 45 days∗ 33%∗ 51 ± 21%∗ ∗ P < 0.05 vs control. # At E:T ratio of 100:1. Conclusions: Mice treated with DC loaded with apoptotic, syngeneic melanoma cells (DC/ApoB-16) or apoptotic, allogeneic melanoma cells (DC/ApoK-1735) had delayed tumor progression and improved survival compared to controls. CTL responses to B-16 cells were seen in both treatment groups, and there was no difference in tumor size, survival, or CTL responses among the treatment groups. We conclude that DC loaded with apoptotic allogeneic melanoma cells may be a practical and effective approach to polyvalent immunotherapy of melanoma. We are currently designing a clinical trial to evaluate the efficacy of this treatment in patients with high-risk disease.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results